UroGen Pharma (URGN) Return on Sales Growth (5y) (2022 - 2026)

UroGen Pharma (URGN) Return on Sales Growth (5y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn -
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 471.84 Bn 467.05 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.13 Bn 114.88 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.01 Bn 61.26 Bn 3.31 Bn
7 Belite Bio 62.34 Bn 62.34 Bn -
8 Argenx Se 55.93 Bn 50.74 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn
10 UroGen Pharma 2.08 Bn 1.93 Bn 46.82 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 3.00
Dec 31, 2025 0.00
Sep 30, 2025 7.00
Jun 30, 2025 82.00
Dec 31, 2024 6,682.00
Sep 30, 2024 7,321.00
Jun 30, 2024 1,490.00
Mar 31, 2024 180.00
Dec 31, 2023 93.00
Sep 30, 2023 73.00
Jun 30, 2023 50.00
Mar 31, 2023 26.00
Dec 31, 2022 67.00
Sep 30, 2022 -2.00
Mar 31, 2022 178.00